#cscc search results
FDA approves adjuvant cemiplimab for high risk cutaneous SCC based on C-POST phase III trial presented at #ASCO2025 #skincancer @OncoAlert @brunolarvol @myESMO #CSCC 350mgQ3Wx4cycles followed by 700mgQ6Wx6cycles High-risk disease criteria: 🔸Nodal: ECE + ≥1 node ≥20 mm or…
#BREAKING: The CHMP has recommended EU approval of our medicine for the adjuvant treatment of cutaneous squamous cell carcinoma (#CSCC) with a high risk of disease recurrence after surgery and radiation. Read more: bit.ly/3JbM05N
FDA Approves Regeneron’s Libtayo® as First Adjuvant Immunotherapy for High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) - For More Information Visit shorturl.at/EXIRq @Regeneron #CSCC #Rare_Diseases #FDA #Squamous_Cell_Carcinoma #OrphanDrugs #Libtayo
#BreakingNews: The U.S. FDA has approved our medicine as an adjuvant treatment for adults with cutaneous squamous cell carcinoma (#CSCC) with high risk of recurrence after surgery and radiation. Learn more about this approval’s potential impact: bit.ly/42zjjX3
Interactive learning. Clinical impact. Asses your mastery of #Immunotherapy advances in #CSCC and gain expert insight from Nikhil I. Khushalani, MD (@DrKhushalani) in this #PeerView #MedEd activity! bit.ly/4muNuXu #Oncology
With ESMO right around the corner, we look forward to sharing updates across our diverse oncology pipeline, including data from our trial in high-risk cutaneous squamous cell carcinoma #CSCC. Learn more about our #ESMO25 data: bit.ly/46UeCK9
💡 Vishal A. Patel, MD, FAAD, FACMS, calls #cemiplimab a game-changer for preventing #CSCC recurrence and urges dermatologists to stay engaged. hubs.li/Q03PJhWj0 #DermTwitter
Adjuvant Cemiplimab Recommended for European Approval in #CSCC. #oncology onclive.com/view/adjuvant-…
Attention Paddock: 2024 Special Saloons & Modsports calendar confirmed - 🏁 Thruxton - May 18 🏁 Silverstone - June 1 🏁 Oulton Park - July 27/28 🏁 Brands Hatch - August 25/26 🏁 Snetterton - September 28 #SpecialSaloonsModsports #CSCC (📸©️ @justinward73)
Cristina Vee, the voice actress for Sailor Mars ☄️ #CSCC #ColoradoSpringsComicon
15yrs ago I encountered videos from #SDCC panels on Supernatural n I was since hell bent on goin I’m going to my 1st #COMICON ever! It’s not in San Diego but I’m geeked just the same Meet #SailorMars in 2024
Action shot of lap 1…I had a great start and gained 3 places 🤩 @Brands_Hatch Indy always gives us exciting racing 👌🏻#CSCC #Elise
Went for a bit of a stroll on my break today, always check the car park, very tasty #Holden parked up, just the right colour for @LUDENClassics! #CSCC #brandshatch Any love out there for the mightly Holden?
📢 Attention Paddock: Special Saloons & Modsports calendar confirmed for 2025 - 🏁 Apr 13 - Donington Park 🏁 Jun 14 - Silverstone 🏁 Jul 26/27 - Oulton Park 🏁 Aug 30/31 - Brands Hatch 🏁 Sept 21 - Castle Combe #SpecialSaloonsModsports #CSCC (📸©️ @Stu_Homer)
Just some of the mix of shapes and sizes in the #CSCC #SpecialSaloons & #Modsports at the #OultonPark #OultonParkGoldCup meeting, one of my favourites being Paul Turner's #Suzuki #SC100 which I remember racing in the #CastleCombeCircuit #SpecialGT in the early '90s as a teenager.
📹 WATCH: Dr Vishal A. Patel @GWCancer discusses the breakthrough in treating high-risk cutaneous squamous cell carcinoma with #FDA-approved cemiplimab, addressing significant patient needs. #CSCC #SkinCancer hubs.li/Q03Q0lLK0
❗FDA approves #cemiplimab (#Libtayo) as the first adjuvant immunotherapy for high-risk #CSCC post-surgery/radiation. hubs.li/Q03NB7WN0 #DermTwitter
💡 Vishal A. Patel, MD, FAAD, FACMS, reflects on leading the landmark C-POST trial that secured FDA approval of #cemiplimab for high-risk #CSCC. hubs.li/Q03Pk4wy0 #SkinCancer #DermTwitter
Interactive learning. Clinical impact. Asses your mastery of #Immunotherapy advances in #CSCC and gain expert insight from Nikhil I. Khushalani, MD (@DrKhushalani) in this #PeerView #MedEd activity! bit.ly/4muNuXu #Oncology
Huge congratulations to our incredible Columbia State Student Bowl teams! Both represented us proudly at the TN Society of Radiologic Technologists Annual Conference in Clarksville and took 1st place! #ColumbiaState #CSCC #RadiologicTechnology #FutureRads #StudentBowlChamps
Big things are happening, the new OhioHealth Hall has broken ground! Enjoy a front row seat as we share monthly updates and watch the progress come to life together! #ohiohealthhall #CSCC #columbus
Adjuvant PD-1 blockade in high-risk #CSCC might soon become the standard. But should it? Divergent ph 3 results highlight uncertainty, while neoadjuvant approaches may offer more with less. Our thoughts in EJCancer 🔽🔽🔽 ejcskn.com/article/S2772-… @MandalaMario @FSpagnoloMD
ejcskn.com
Is earlier better? Rethinking timing of immunotherapy in cutaneous squamous cell carcinoma
To the Editor,
📹 WATCH: Dr Vishal A. Patel @GWCancer discusses the breakthrough in treating high-risk cutaneous squamous cell carcinoma with #FDA-approved cemiplimab, addressing significant patient needs. #CSCC #SkinCancer hubs.li/Q03Q0lLK0
💡 Vishal A. Patel, MD, FAAD, FACMS, calls #cemiplimab a game-changer for preventing #CSCC recurrence and urges dermatologists to stay engaged. hubs.li/Q03PJhWj0 #DermTwitter
💡 Vishal A. Patel, MD, FAAD, FACMS, reflects on leading the landmark C-POST trial that secured FDA approval of #cemiplimab for high-risk #CSCC. hubs.li/Q03Pk4wy0 #SkinCancer #DermTwitter
❗Regeneron’s #cemiplimab #Libtayo earns EU backing as the first adjuvant immunotherapy for high-risk #CSCC post-surgery and radiation, cutting recurrence risk by 68% in trials. hubs.li/Q03Pk53R0 #SkinCancer #DermTwitter
FDA approves Libtayo as adjuvant therapy for high-risk cutaneous squamous cell carcinoma! 🌟 Trial data show major improvements in disease-free survival. Read more specialtypharmacycontinuum.com/a/3TIBAA/t #CSCC #Oncology #FDA
Adjuvant Cemiplimab Recommended for European Approval in #CSCC. #oncology onclive.com/view/adjuvant-…
#BREAKING: The CHMP has recommended EU approval of our medicine for the adjuvant treatment of cutaneous squamous cell carcinoma (#CSCC) with a high risk of disease recurrence after surgery and radiation. Read more: bit.ly/3JbM05N
❗FDA approves #cemiplimab (#Libtayo) as the first adjuvant immunotherapy for high-risk #CSCC post-surgery/radiation. hubs.li/Q03NB7WN0 #DermTwitter
With ESMO right around the corner, we look forward to sharing updates across our diverse oncology pipeline, including data from our trial in high-risk cutaneous squamous cell carcinoma #CSCC. Learn more about our #ESMO25 data: bit.ly/46UeCK9
The #FDA has approved #cemiplimab‑rwlc for the adjuvant treatment of adults with cutaneous squamous cell carcinoma (#CSCC) at high risk of recurrence following #surgery and #radiation. 🔗Learn more about the #CPOST and the #approval here: oncdata.com/cemiplimab-app…
FDA approves adjuvant cemiplimab for high risk cutaneous SCC based on C-POST phase III trial presented at #ASCO2025 #skincancer @OncoAlert @brunolarvol @myESMO #CSCC 350mgQ3Wx4cycles followed by 700mgQ6Wx6cycles High-risk disease criteria: 🔸Nodal: ECE + ≥1 node ≥20 mm or…
リブタヨがCSCC術後補助療法でFDA承認──再発・死亡リスク68％低減 stellanews.life/technology_cat… #Libtayo #Cemiplimab #CSCC #CutaneousSquamousCellCarcinoma #AdjuvantTherapy #PD1Inhibitor #CancerImmunotherapy #FDAApproval #CPOSTTrial #Regeneron #OncologyNews
JUST IN: U.S. FDA has approved the PD-1 inhibitor cemiplimab-rwlc (Libtayo, @Regeneron Pharmaceuticals, Inc.) as an adjuvant treatment for adult patients with cutaneous #squamouscell #carcinoma (#cSCC) at high risk of recurrence after surgery & radiation. jdnppa.com/cemiplimab-now…
FDA Approves Regeneron’s Libtayo® as First Adjuvant Immunotherapy for High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) - For More Information Visit shorturl.at/EXIRq @Regeneron #CSCC #Rare_Diseases #FDA #Squamous_Cell_Carcinoma #OrphanDrugs #Libtayo
🚨 BREAKING: The #FDA has approved cemiplimab as an adjuvant treatment for high-risk cutaneous squamous cell #carcinoma. #CSCC #SkinCancer #FDAApproval hubs.li/Q03MQz2h0
FDA Approves Regeneron’s Libtayo® as First Adjuvant Immunotherapy for High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) - For More Information Visit shorturl.at/EXIRq @Regeneron #CSCC #Rare_Diseases #FDA #Squamous_Cell_Carcinoma #OrphanDrugs #Libtayo
Attention Paddock: 2024 Special Saloons & Modsports calendar confirmed - 🏁 Thruxton - May 18 🏁 Silverstone - June 1 🏁 Oulton Park - July 27/28 🏁 Brands Hatch - August 25/26 🏁 Snetterton - September 28 #SpecialSaloonsModsports #CSCC (📸©️ @justinward73)
Thank you @mehrdadmohseni0 and the @theNCI staff for hosting a terrific #clincaltrials planning meeting (CTPM) for underserved patients with #cscc #skin #cancer @evanlipson @TheMillerLab @sueyom @KaramLab @HeadNeckMD @KYTsaiLab @BrianGastmanMD @ShlomoKoyfmanMD @HowardK39084949
Action shot of lap 1…I had a great start and gained 3 places 🤩 @Brands_Hatch Indy always gives us exciting racing 👌🏻#CSCC #Elise
FDA approves adjuvant cemiplimab for high risk cutaneous SCC based on C-POST phase III trial presented at #ASCO2025 #skincancer @OncoAlert @brunolarvol @myESMO #CSCC 350mgQ3Wx4cycles followed by 700mgQ6Wx6cycles High-risk disease criteria: 🔸Nodal: ECE + ≥1 node ≥20 mm or…
Surgeon-to-be Dr Elissa Zhang presenting Westmead data in Rome #IFHNOS23 on primary radiation for unresectable #cSCC. Durable results in a compromised cohort. @sundap15 @WestmeadInst @traumaoncoplast @RACSurgeons @anzhncs @sueyom
Congratulations to the #C-POST team!!! Huge step forward for patients with high risk, resected #cscc #skin #cancer @Regeneron @TROGfightcancer @ASCOPost @NEJM
Even Clawdette Cougar - Columbus State’s mascot is looking forward to students and graduates continuing their celebrations and community building at next week’s CougarCon!! #cougarcon #cscc #graduation
What is the prognosis of pts with adv #CSCC receiving ICI who discontinue tp after an initial response? Published on @JGeriOnc by @boutrosand and @FSpagnoloMD this analysis investigating if a short exposure to anti-PD-1 can be associated with long-term responses. @OncoAlert
Great couple of days @theNCI with @ShlomoKoyfmanMD and Dr. Julie Bauman co-chairing a much needed Clinical Trials Planning Meeting (CTPM) for #immunocompromised patients with #CSCC #skin #cancer @SkinAwareness @hncalliance @MDAndersonNews #hncsm @NRGonc @eaonc @ALLIANCE_org
📢 Attention Paddock: Special Saloons & Modsports calendar confirmed for 2025 - 🏁 Apr 13 - Donington Park 🏁 Jun 14 - Silverstone 🏁 Jul 26/27 - Oulton Park 🏁 Aug 30/31 - Brands Hatch 🏁 Sept 21 - Castle Combe #SpecialSaloonsModsports #CSCC (📸©️ @Stu_Homer)
The deadline to request to be a vendor for CougarCon 2024 is April 12, and the presenter forms will be due April 19. Get your forms in now! Link Tree in Bio. Don't miss the opportunity to be a part of the CougarCon magic! #cougarcon #cougarcon2024 #cscc #convention #popculture
THANK YOU! CougarCon 2024 was an absolute pleasure because of you all. There was so much love and support that went into this event, and we couldn’t have done it without every single one of you! #cougarcon #cougarcon2024 #cscc #convention
Thank you Dr. Caroline Robert @GustaveRoussy for the scholarly discussion of #neoadjuvant #immunotherapy in resectable #CSCC during the #melanoma and #skin session with fellow experts @OmidHamidMD and @ProfGLongMIA @myESMO #ESMO2023
Just some of the mix of shapes and sizes in the #CSCC #SpecialSaloons & #Modsports at the #OultonPark #OultonParkGoldCup meeting, one of my favourites being Paul Turner's #Suzuki #SC100 which I remember racing in the #CastleCombeCircuit #SpecialGT in the early '90s as a teenager.
Went for a bit of a stroll on my break today, always check the car park, very tasty #Holden parked up, just the right colour for @LUDENClassics! #CSCC #brandshatch Any love out there for the mightly Holden?
Something went wrong.
Something went wrong.
United States Trends
- 1. Penn State 21.9K posts
- 2. Mendoza 18.7K posts
- 3. Gus Johnson 6,139 posts
- 4. #iufb 3,945 posts
- 5. $SSHIB 1,285 posts
- 6. Omar Cooper 8,894 posts
- 7. Sayin 66.8K posts
- 8. Sunderland 151K posts
- 9. Estevao 27.4K posts
- 10. #UFCVegas111 3,638 posts
- 11. Iowa 18.5K posts
- 12. Jim Knowles N/A
- 13. Texas Tech 13.1K posts
- 14. James Franklin 7,991 posts
- 15. Happy Valley 1,805 posts
- 16. Oregon 32.6K posts
- 17. Arsenal 250K posts
- 18. Neto 24.4K posts
- 19. Garnacho 20.2K posts
- 20. WHAT A CATCH 10.9K posts